Transcription of US-17452 --------------------------------- DOSAGE …
{{id}} {{{paragraph}}}
Example: marketing
US-17452 --------------------------------- DOSAGE …
US-17452 HIGHLIGHTS OF PRESCRIBING INFORMATIONT hese highlights do not include all the information needed to use lynparza safely and effectively. See full prescribing information for (olaparib) tablets, for oral useInitial Approval: 2014------------------------------------ -- RECENT MAJOR CHANGES -------------------------------------Ind ications and Usage ( ) 1/2018 DOSAGE and Administration ( ) 1/2018 Warnings and Precautions (5) 1/2018---------------------------------- ---- INDICATIONS AND USAGE --------------------------------------Ly nparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:Ovarian cancer for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. ( ) for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
US-17452. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LYNPARZA safely and . effectively.
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: